ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01ED01 | B | Crizotinib - 250mg | 9727 | 169618/1 | XALKORI | 250mg | 60 | Capsule | Oral | Droguerie Fattal S.A.L. | Pfizer Manufacturing Deutschland GmbH | Germany | 347,644,061 L.L | 2.44 | E2 | pfizer Canada ULC | Canada | 12/12/20 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01ED01 | B | Crizotinib - 250mg | 9727/388 | 169618/1 | XALKORI | 250mg | 60 | Capsule | Oral | Droguerie Fattal S.A.L. | Pfizer Manufacturing Deutschland GmbH | Germany | L.L | 2.44 | E2 | pfizer Canada ULC | Canada | 05/02/20 |